Jan 11, 2021 / 01:20PM GMT
Tycho W. Peterson - JPMorgan Chase & Co, Research Division - Senior Analyst
All right. Good morning, everybody. Welcome to day 1 of the JPMorgan Healthcare Conference. I'm pleased to introduce our next company, Catalent. (Operator Instructions)
And with that, let me turn it over to John.
John R. Chiminski - Catalent, Inc. - Chairman & CEO
Great. Thanks, Tycho. Good morning, everybody. I'm pleased to be with you in this virtual format to share Catalent's story.
Before diving into the presentation, let me first draw your attention to Slides #2 and 3, which note our forward-looking statements and also non-GAAP financials. I also encourage you to review our SEC filings to understand the risks and uncertainties that may bear on our operating results and financial condition.
So let's turn to Page 4. For decades, Catalent has been the leading global provider of advanced dosage delivery technologies and drug development and manufacturing solutions. As a leading CDMO, we continue to differentiate ourselves through investing in
Catalent Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot